NCT05333692

Oral Nutritional Supplementation of Hemodialysis Patients

Name: Clinical Trial NCT05333692
Creator: Fresenius Kabi Taiwan Ltd.
Keywords: Hemodialysis Complication, Fresubin® Protein Energy DRINK, dietary supplement, clinical trial, Taiwan

Fresenius Kabi Taiwan Ltd.·ClinicalTrials.gov·dietary supplementCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Hemodialysis Complication
Drug/Device/Intervention: Fresubin® Protein Energy DRINK
Study type: Interventional
Intervention type: dietary supplement

Sponsor & location

Primary sponsor: Fresenius Kabi Taiwan Ltd.
Location: Taichung, Taiwan

Timeline & enrollment

Phase: N/A
Start date: Jul 01, 2020
End date: May 06, 2021
Enrollment: 90 participants

Primary outcome

Serum Albumin level change

Summary

This study is aimed to demonstrate that increase in serum albumin concentration (week 8 -baseline) after test treatment (Fresubin® Protein Energy DRINK), a standard ONS, is not relevantly smaller than that after control treatment with NEPRO®.

ICD-10 classifications

Kidney dialysisOther dialysisCare involving dialysisMechanical complication of vascular dialysis catheterHaemoglobinuria due to haemolysis from other external causes

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05333692
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05333692 through Pure Global AI's free database. This phase not specified trial is sponsored by Fresenius Kabi Taiwan Ltd. and is currently Completed. The study focuses on Hemodialysis Complication. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.